Evidence supporting the use of: Ethylenediaminetetraacetic acid (EDTA)
For the health condition: Heavy Metal Poisoning
Synopsis
Source of validity: Scientific
Rating (out of 5): 5
EDTA (ethylenediaminetetraacetic acid) is scientifically validated for use in treating heavy metal poisoning, particularly lead poisoning. EDTA acts as a chelating agent: it binds to metal ions in the bloodstream, forming complexes that are more easily excreted by the kidneys. This mechanism reduces the concentration of toxic metals in the body. The use of EDTA for this purpose was introduced in the 1950s, initially to treat lead poisoning among industrial workers and children. Its efficacy and safety profile have been established through numerous clinical studies, and it is approved by the U.S. Food and Drug Administration (FDA) for treating lead poisoning and for use in certain cases of other metal toxicities (such as cadmium). The standard form used is calcium disodium EDTA, as disodium EDTA can cause hypocalcemia. EDTA is not used for mercury or arsenic poisoning, where other chelators like dimercaprol or DMSA are preferred. Mainstream toxicology and medical textbooks include EDTA chelation therapy as a first-line treatment for acute and chronic lead poisoning. Thus, the use of EDTA for heavy metal poisoning is grounded in robust scientific evidence, including randomized controlled trials and decades of clinical experience.
More about Ethylenediaminetetraacetic acid (EDTA)
More about Heavy Metal Poisoning
Other health conditions supported by Ethylenediaminetetraacetic acid (EDTA)
Chemical PoisoningCirculation (poor)
Heavy Metal Poisoning
Lead Poisoning